13 Best Low Priced Pharma Stocks to Buy Now

Page 12 of 12

1. Sarepta Therapeutics Inc. (NASDAQ:SRPT)

Share Price as of July 14: $19.23

Number of Hedge Fund Holders: 47

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is one of the best low priced pharma stocks to buy now. Towards the end of June, Sarepta Therapeutics started facing a temporary suspension of shipments for ELEVIDYS, which is its gene therapy for Duchenne muscular dystrophy/DMD, specifically for non-ambulatory patients. This decision was announced around June 16 and followed two reported cases of fatal acute liver failure in non-ambulatory patients who received the treatment.

The most recent death involved a 15-year-old patient. These severe side effects have led Sarepta to pause the ENVISION Phase 3 confirmatory trial (SRP-9001-303), which includes both older ambulatory and non-ambulatory individuals, to allow for protocol updates and regulatory discussions.

DMD primarily affects males, with symptoms typically appearing between the ages of 2 and 3. It progresses rapidly and leads to the gradual loss of muscle function in the skeletal, heart, and lung muscles. DMD is caused by a mutation in the DMD gene, which is responsible for producing dystrophin, a protein vital for muscle cell integrity.

Sarepta Therapeutics Inc. (NASDAQ:SRPT) is a commercial-stage biopharmaceutical company that discovers and develops RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases.

While we acknowledge the potential of SRPT to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SRPT and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. Insider Monkey focuses on uncovering the best investment ideas of hedge funds and insiders. Please subscribe to our free daily e-newsletter to get the latest investment ideas from hedge funds’ investor letters by entering your email address below.

Page 12 of 12